A story of bio-innovation


Although Quorus Biotech was officially formed as a company in 2011 our roots can be traced back to 2001. In the year 2001 the Government introduced a South African National Biotechnology Development Strategy to advance and commercialise the emerging biotechnology sector. In the same year a biotechnology company called Synexa Life Sciences was founded. They were one of the first biotechnology companies to receive funding as part of the National Biotechnology Strategy.

Initially, the Quorus bioprocessing plaform was developed as part of a business unit within Synexa, one of the first biotechnology companies to be funded as part of the National Biotechnology Development Strategy.


With the market introduction and widespread acceptance of single-use technologies in biomanufacturing in the mid-2000s, the Quorus technology platform development team was well positioned to adopt the trend. This resulted in the development of a number of innovative single-use membrane biorectors as part of a Quorus product and bioprocessing portfolio.


After a Synexa company restructuring process in 2009 and 2010, and having an established core intellectual property (IP) portfolio, the Quorus business unit separated from Synexa Life Sciences. Quorus Biotech became a wholly independent spin-off company and the restructuring attracted venture capital funding from the South African IDC (Industrial Development Corporation)


Quorus Biotech has more than a decade of experience in the development of adherent cell line technology platforms for micriobial and mammalian cell culture. We offer a full range of bioprocessing and development expertise to support the product lifecycles of our clients.

Meet the team

Scientists, engineers and technicians